JamesHEssellMD

Oncology • Blue Ash, OH

Oncology Hematology Care, Inc.

Join to view full profile

Dr. Essell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Essell's full profile

Already have an account?

Office
4725 E Galbraith Rd
Ste 320
Blue Ash, OH 45236
Phone+1 513-751-2273

Fax+1 513-751-1840
Is this information wrong?

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1988 - 1991
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1985 - 1988
University of Cincinnati College of MedicineClass of 1985

Certifications & Licensure

OH State Medical License 1981 - 2025
KY State Medical License 1997 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Top MD Consumers Checkbook

Clinical Trials

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2006 Jun 01
Terminated
Phase 2
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
Completed
Phase 2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, John M Pagel, Jerald P Radich, Min Fang, David A Rizzieri, Guido Marcucci, Stephen A Strickland, Mark R Litz...> ;Leukemia. 2024 Jan 1
52 citations
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transpla...
Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C Hildebrandt, John E Godwin, Patrick M Reagan, Nina Wagner-Johnston, James Essel...> ;The Lancet. Oncology. 2022 Aug 1
1 citations
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
Tycel Phillips, Mark Brunvand, Andy I. Chen, James Essell, Annalisa Chiappella, Catherine Diefenbach, Ji Cheng, David Ramies, Jamie Hirata, Franck Morschhauser, Ian W....> ;American Journal of Hematology. 2021 Nov 3
11 citations
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Matthew S. Davids, Owen A. O'Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, Nilanjan Ghosh, Bruce D. Cheson, Enric...> ;Blood Advances. 2021 Sep 21
64 citations
ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
Madan Jagasia, Aleksandr Lazaryan, Carlos Bachier, Amandeep Salhotra, Daniel J. Weisdorf, Behyar Zoghi, James Essell, Laurie S. Green, Olivier Schueller, Jeegar Patel,...> ;Journal of Clinical Oncology. 2021 Apr 20
8 citations
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating ag...
Fevzi Firat Yalniz, Jesus G. Berdeja, Michael B. Maris, Roger M. Lyons, James A. Reeves, James Essell, Prapti A. Patel, Mikkael A. Sekeres, Amanda Hughes, Silvia Mappa...> ;British Journal of Haematology. 2020 Feb 1
9 citations
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia
John M. Pagel, Megan Othus, Guillermo Garcia-Manero, Min Fang, Jerald P. Radich, David A. Rizzieri, Guido Marcucci, Stephen A. Strickland, Mark R. Litzow, M. Lynn Savo...> ;JCO Oncology Practice. 2020 Jan 27
30 citations
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Matthew S. Davids, Bryone J. Kuss, Peter Hillmen, Marco Montillo, Carol Moreno, James Essell, Nicole Lamanna, Zsolt Nagy, Constantine S. Tam, Stephan Stilgenbauer, Pao...> ;Clinical Cancer Research. 2020 Jan 21
20 citations
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
John M. Burke, Andrei R. Shustov, James Essell, Dipti Patel-Donnelly, Jay Yang, Robert T. Chen, Wei Ye, Wen Shi, Sarit Assouline, Jeff P. Sharman> ;Clinical Lymphoma, Myeloma & Leukemia. 2018 Aug 1
140 citations
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation...
Howard A. Burris, Ian W. Flinn, Manish R. Patel, Timothy S. Fenske, Changchun Deng, Danielle M. Brander, Martin Gutierrez, James Essell, John G. Kuhn, Hari P. Miskin, ...> ;The Lancet. Oncology. 2018 Apr 1
1 citations
A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
William B. Donnellan, Jesus G. Berdeja, Diana Shipley, Edward Arrowsmith, David Wright, Scott D. Lunin, Richard H. Brown, James Essell, Ian W. Flinn> ;The Oncologist. 2017 Oct 1
4 citations
Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose c...
Jesus G. Berdeja, Todd M. Bauer, Edward Arrowsmith, James Essell, Patrick Murphy, James A. Reeves, Ralph V. Boccia, William B. Donnellan, Ian W. Flinn> ;British Journal of Haematology. 2017 Apr 1
74 citations
Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes
Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G. Berdeja, Yasmin Abaza, Elias J. Jabbour, James Essell, Roger M. Lyons, Farhad Ravandi, Michael B. Maris, B...> ;Cancer. 2017 Mar 15
117 citations
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
Ruben Niesvizky, Ian W. Flinn, Robert M. Rifkin, Nashat Y. Gabrail, Veena Charu, Billy Clowney, James Essell, Yousuf Gaffar, Thomas A. Warr, Rachel Neuwirth, Yanyan Zh...> ;Journal of Clinical Oncology. 2015 Jun 8
76 citations
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
Jesus G. Berdeja, Lowell L. Hart, Joseph R. Mace, Edward Arrowsmith, James Essell, Rami Owera, John D. Hainsworth, Ian W. Flinn> ;Haematologica. 2015 May 1
1 citations
Medulloblastoma in an Adult With Late Extraneural Metastases to the Mediastinum.
Abhimanyu Ghose, John C. Morris, John C. Breneman, James Essell, Jiang Wang, Sadia Benzaquen> ;Journal of Investigative Medicine High Impact Case Reports. 2014 Apr 17
32 citations
Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics
Mitchell E. Horwitz, Ivan Spasojevic, Ashley Morris, Marilyn J. Telen, James Essell, Cristina Gasparetto, Keith M. Sullivan, Gwynn D. Long, John P. Chute, Nelson J. Ch...> ;Biology of Blood and Marrow Transplantation. 2007 Dec 1
48 citations
Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease
Paul J. Shaughnessy, Carlos Bachier, Michael Grimley, Cesar O. Freytes, Natalie S. Callander, James Essell, Neal Flomenberg, George B. Selby, C.F. LeMaistre> ;Biology of Blood and Marrow Transplantation. 2005 Mar 1
22 citations
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.
Mace L. Rothenberg, Poching Liu, Sharon P. Wilczynski, William A. Nahhas, Gaye L. Winakur, Caroline S. Jiang, Carol M. Moinpour, Ben Lyons, Geoffrey R. Weiss, James H....> ;Gynecologic Oncology. 2004 Dec 1
124 citations
Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation: A Randomized, Double-Blind, Placebo-Controlled Trial
James H. Essell, Mark T. Schroeder, Glenn S. Harman, Ronald Halvorson, Vernon Lew, Natalie S. Callander, Michael Snyder, Stacey K. Lewis, Jeffrey P. Allerton, James M....> ;Annals of Internal Medicine. 1998 Jun 15
29 citations
Oral cavity complications of bone marrow transplantation.
Drore Eisen, James Essell, Edward R. Broun> ;Seminars in Cutaneous Medicine and Surgery. 1997 Dec 1
72 citations
Abciximab-associated profound thrombocytopenia : Therapy with immunoglobulin and platelet transfusion
Dean J. Kereiakes, James H. Essell, Charles W. Abbottsmith, Thomas M. Broderick, John Paul Runyon> ;The American Journal of Cardiology. 1996 Nov 15
119 citations
Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass
James H. Essell, Thomas J. Martin, John Salinas, James M. Thompson, Vernon C. Smith> ;Journal of Cardiothoracic and Vascular Anesthesia. 1993 Aug 1
42 citations
Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.
James H. Essell, James M. Thompson, Glenn S. Harman, Ronald Halvorson, M J Snyder, Natalie S. Callander, D J Clement> ;Bone Marrow Transplantation. 1992 Oct 1
62 citations
Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclop...
James H. Essell, James M. Thompson, Glenn S. Harman, Ronald Halvorson, Michael J. Snyder, Robert Johnson, James R. Rubinsak> ;Blood. 1992 May 15
Join now to see all

Abstracts/Posters

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) _ Long-Term Follow-up of a Phase 2a Study (KD025-208)
James Essell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 DataClinically Relevant Abs...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018